The Potential Impact of the Coronavirus (COVID-19) Pandemic on Hostile M&A and Shareholder Activism in the U.S.
The Potential Impact of the Coronavirus (COVID-19) Pandemic on Hostile M&A and Shareholder Activism in the U.S.
Over the last month, each of the major stock market indices has experienced extreme volatility and a broad-based decline in value, largely in response to the coronavirus pandemic. The bellwether Dow Jones Industrial Average has declined 34%, while the S&P 500, the Nasdaq Composite and the Russell 2000 indices have experienced declines of 32%, 29% and 40%, respectively. The hospitality, retail, transportation and oil and gas industries have been hit particularly hard, with the oil and gas industry confronting a second issue with Saudi Arabia initiating an oil price war with Russia and the subsequent price of oil and oil-related stocks plummeting.
Conventional wisdom would suggest a resulting increase in hostile M&A activity is likely to occur, as opportunistic acquirors take advantage of companies that are undervalued and, in some cases, particularly vulnerable due to liquidity concerns. During the financial crisis of 2008, the number of unsolicited public offers for U.S. targets spiked 54% from 41 to 63 over the prior year (and then dropped to normalized historical levels in the mid-30s for each of the next three years).[1] Similarly, activist shareholders were emboldened to launch 126 and 133 proxy fights in 2008 and 2009, respectively, against U.S. companies – more than in any year since.[2]
Number of Unsolicited Public U.S.-Target M&A Deals
We note in this regard that U.S. corporations may be more vulnerable to opportunistic hostile bids than at any time in recent history, with many companies having dismantled valuable takeover defenses over the last two decades. For example, 10% of S&P 500 companies currently have classified boards, down from 39% in 2010 and 60% in 2000.[3] Likewise, relatively few companies now have “poison pill” shareholder rights plans in place (although many companies have poison pills “on the shelf” and ready to be deployed). At the same time, other companies have built up massive cash balances over the course of the economic expansion of the last decade and are capable of deploying that cash toward acquisitions. Private equity funds have also built up lots of dry powder, with the industry holding a total of $1.5 trillion in unspent capital available for acquisitions at the end of 2019.[4]
For those funds who view the current decline in the markets as temporary, the current situation offers a tremendous opportunity to advance investment objectives. For example, Carl Icahn has increased his stake in (1) Hertz Global Holdings Inc. (HTZ) to 38.9% after purchasing 11.4 million shares at $7.43/share,[5] (2) Newell Brands Inc. (NWL) to 10.7% after purchasing 2.58 million shares at 13.41/share,[6] and (3) Occidental Petroleum Corp. (OXY) to 9.9% from 2.5% at a range of $17.11 – $12.68/share.[7] To put those purchases in context, at market close on January 31, 2020, HTZ was priced at $15.76/share, NWL at $19.53/share and OXY at $39.72/share.
Indeed, several companies have already adopted poison pills following the plunge in their stock price over the last couple of weeks, resulting in stock prices they believe do not nearly reflect their companies’ intrinsic value. Some of these companies, such as Delek US Holdings, Inc., have already been grappling with shareholder activism, while others, such as The Williams Companies, Inc. and Dave & Buster’s Entertainment, Inc., have adopted poison pills proactively to fend off opportunistic bidders and activist hedge funds. All of these poison pills have terms of no longer than one year, a term that qualifies for less restrictive treatment from the proxy advisory firms.[8]
At least in the short term, there may be some countervailing considerations that could dampen or delay the otherwise expected wave of shareholder activism and unsolicited M&A.
There is little doubt that hostile M&A and shareholder activism will increase if stock prices remain at the current depressed levels. While there may be good reason to believe that a new wave of hostile M&A and shareholder activism will be delayed until current healthcare and market conditions stabilize, we can be certain that internal M&A and corporate development departments, investment bankers and other industry participants are already working to identify potential acquisition targets. While this bodes well for a return to heightened activity levels in the broader M&A market, it also may portend a wave of hostile M&A once the time is right. Company boards and management would be well advised to get out in front by reviewing their takeover defenses with counsel, reconsidering their plans for maximizing shareholder value and considering proactive outreach to their shareholders.
[1] Thomson Reuters.
[2] FactSet.
[3] Deal Point Data; ISS Analytics.
[4] “[Private equity firms] have amassed almost $1.5 trillion in unspent capital, the highest year-end total on record, according to data compiled by Preqin.” See Melissa Karsh and Benjamin Robertson, Private Equity Is Starting 2020 With More Cash Than Ever Before, Bloomberg (Jan. 1, 2020), available at: https://www.bloomberg.com/news/articles/2020-01-02/private-equity-is-starting-2020-with-more-cash-than-ever-before.
[5] TipRanks, Billionaire Carl Icahn Picks up These 2 Stocks on the Dip, Yahoo! Finance (Mar. 15, 2020), available at: https://finance.yahoo.com/news/billionaire-carl-icahn-picks-2-115019189.html?mod=article_inline.
[6] Id.
[7] “‘I’m just glad I can afford to quadruple down,’ Mr. Icahn said.” Cara Lombardo, Carl Icahn Boosts Occidental Stake to Almost 10% as Shares Plummet, Wall Street Journal (Mar. 11, 2020), available at: https://www.wsj.com/articles/carl-icahn-boosts-occidental-stake-to-almost-10-as-shares-plummet-11583969050.
[8] Proxy advisory services, such as Institutional Shareholder Services Inc. (ISS), may recommend a vote against or withhold from directors who adopt a poison pill without stockholder approval. However, ISS also will consider votes on a case-by-case basis if the poison pill has a term of one year or less, depending on the disclosed rationale for the adoption and other factors (such as a commitment to put any renewal to a stockholder vote). ISS United States Proxy Voting Guidelines Benchmark Policy Recommendations, published Nov. 18, 2019, pp. 12-13.
[9] However, this doesn’t necessarily cut in favor of management, as the retail shareholder base – which tends to support incumbent management – may experience a higher percentage of distracted shareholders than large institutional shareholders, giving the large institutional shareholders even more weight than they otherwise have in the outcome of the contest. See Alon Brav, Matthew D. Cain, Jonathon Zytnick, Retail Shareholder Participation in the Proxy Process: Monitoring, Engagement, and Voting, European Corporate Governance Institute – Finance Working Paper No. 637/2019 (Nov. 6, 2019), at 22, 43, available at: https://ssrn.com/abstract=3387659 (Reporting that in a survey of proxy votes in U.S. companies from 2015-2017, retail shareholders supported 94% of management sponsored proposals and noting that, “The support rates measured at the retail account level are higher than those reported when support is measured at the shareholder level.”); see also Gretchen Morgenson, Small Investors Support the Boards. But Few of Them Vote., New York Times (Oct. 6, 2017), available at: https://www.nytimes.com/2017/10/06/business/small-investors.html.
[10] Unocal Corp. v. Mesa Petroleum Co., 493 A.2d 946, 954-955 (Del. 1985).
[11] Air Prods. & Chems., Inc. v. Airgas, Inc., 16 A.3d 48, 124 (Del. Ch. 2011); Unitrin, Inc. v. Am. Gen. Corp., 651 A.2d 1361, 1384 (Del.1995).
[12] Stahl v. Apple Bancorp, Inc., 579 A.2d 1115, 1124-1125 (Del. Ch. 1990) (“The essence of the Unocal form of review is a judicial assessment of the proportionality of a response to a threat.”).
Practices